Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | CHIP-AML22 master and linked trial: gemtuzumab ozogamicin and quizartinib in newly diagnosed AML

Gertjan Kaspers • 9 Dec 2023
ASH 2023
Acute Myeloid Leukemia Leukemia Antibodies Gemtuzumab ozogamicin Quizartinib Venetoclax
CHIP-AML22

Gertjan Kaspers, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, introduces the CHIP-AML22 (EU CT: 2023-504999-25) study by the NOPHO-DB-SHIP consortium, which will investigate gemtuzumab ozogamicin in pediatric patients with newly diagnosed acute myeloid leukemia (AML). A linked Phase II trial (EU CT: 2023-505000-27-00) will assess the FLT3-inhibitor quizartinib. Enrollment for both of these trials is underway globally. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gertjan Kaspers

1:34
AML2012 trial: daunorubicin-based induction therapies in pediatric AML
Gertjan Kaspers • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals